Welcome to our dedicated page for CHIMERA INVESTMENT SEC filings (Ticker: CIMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chimera Investment Corporation filings document the public-company disclosures behind CIMO, the issuer's 9.250% Senior Notes due 2029. The filing record identifies the notes alongside Chimera's common stock, cumulative redeemable preferred stock series, 9.000% Senior Notes due 2029, and 8.875% Senior Notes due 2030, all listed on the New York Stock Exchange.
Material-event reports include financial results, furnished earnings releases, and investor presentation materials. Proxy statements cover governance and shareholder voting matters for the issuer, while registration and exchange-listing disclosures describe the securities outstanding within Chimera Investment Corporation's capital structure.
Chimera Investment Corporation reported Q2 2026 results for a mortgage portfolio with total assets of 16,045,048 (dollars in thousands), up from 15,808,542 at December 31, 2025. Agency MBS at fair value grew to 5,264,559, while loans held for investment declined to 7,890,790 as sales and principal paydowns continued.
Net interest income increased to 70,509 (dollars in thousands) from 66,010 in Q2 2025, but the provision for credit losses rose to 7,192 from 4,409 and large net unrealized and realized losses on financial instruments reduced profitability. For the first half, total other income (losses) was (61,971) versus 138,660 a year earlier, and other expenses rose to 102,431 from 61,182. This produced a six‑month net income (loss) of (26,541) compared with 202,747, and net income (loss) available to common shareholders of (69,019) versus 159,964, with basic EPS of $(0.82) versus $1.97. Total stockholders’ equity declined to 2,415,626 (dollars in thousands) from 2,572,694 after common dividends of 77,100 and preferred dividends of 42,478 in the first half of 2026.
Chimera Investment Corporation declared third quarter 2026 cash dividends on all four series of its preferred stock: $0.50 per share for its 8.00% Series A Cumulative Redeemable Preferred Stock, $0.6111 for Series B, $0.5578 for Series C, and $0.5984 for Series D. Each dividend is payable on September 30, 2026 to preferred shareholders of record on September 1, 2026, with an ex-dividend date of September 1, 2026.
The Series B, C and D dividends reflect floating annual dividend rates of 9.77804%, 8.73004% and 9.36604%, respectively, each equal to three-month CME Term SOFR plus a 0.26161% spread adjustment and a stated spread. Chimera is an internally managed REIT focused on U.S. residential mortgage and real estate-related assets.
Chimera Investment Corporation reported second-quarter 2026 results with a GAAP net loss available to common shareholders of $4.0 million, or $(0.05) per diluted share, but generated Earnings available for distribution (EAD) of $39 million, or $0.46 per diluted common share. This EAD level supported the quarterly common dividend of $0.45 per share, and EAD for the first half of 2026 totaled $1.00 per share.
GAAP book value per common share was $17.75 at June 30, 2026, and economic return, defined as the change in GAAP book value plus the common dividend, was (0.76)% for the quarter. Total assets were $16.0 billion and stockholders’ equity $2.4 billion, with GAAP leverage of 5.6:1 and recourse leverage of 3.3:1. Liquidity included $444 million of cash and $212 million of unencumbered assets.
The Investment Portfolio segment completed two re-securitizations of residential mortgage loans totaling $487 million and purchased $122 million of newly originated HomeXpress loans, bringing retained loans to $301 million. The Residential Origination segment produced $1.1 billion of volume, earned net income of $9 million and EBTDA of $12 million, corresponding to an annualized EBTDA ROE of 17.3%.
Vanguard Capital Management reports beneficial ownership of 4,187,562 shares of Chimera Investment Corp common stock, representing 5% of the class as of June 30, 2026. The firm holds sole voting power over 617,619 shares and sole dispositive power over all 4,187,562 shares, with no shared voting or dispositive power.
The position reflects securities beneficially owned or deemed beneficially owned by Vanguard Capital Management LLC and certain affiliated entities and business divisions, including various Vanguard asset management and advisory entities and Vanguard funds and managed accounts over which they exercise voting and/or dispositive power. Vanguard entities and managed accounts have rights to dividends and sale proceeds for these securities, but no other single person’s interest exceeds 5% of the class.
Mills Susan reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Susan Mills reported an award of 11,263 restricted stock units (RSUs) tied to Chimera common stock. Each RSU is economically equivalent to one share of common stock and is scheduled to vest on the earlier of June 11, 2027 or the next annual stockholders meeting. The award will be settled entirely in shares of Chimera common stock. Following this grant, Mills reports beneficial ownership of 37,757 shares, including the RSUs.
STILL DEBRA reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Debra Still received a grant of 11,263 restricted stock units (RSUs) of common stock as compensation. The award was recorded at a price of $0.00 per share, indicating a non-cash equity grant rather than an open-market purchase.
The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date on June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in shares of Chimera common stock. After this grant, Still directly holds 60,706 shares of Chimera common stock. Each RSU has the economic equivalent of one share of Chimera common stock.
Chavers Kevin Gerald reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Kevin Gerald Chavers reported an equity award of 11,263 restricted stock units (RSUs) tied to Chimera common stock. The RSUs, each economically equal to one share, were granted at no cash cost and will vest on the earlier of the first anniversary of the June 11, 2026 grant date or the next annual stockholders meeting, then be settled entirely in shares. After this grant, Chavers holds 50,506 shares of Chimera common stock.
Walsh Cynthia B reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Cynthia B. Walsh received an equity award of 11,263 shares of common stock in the form of restricted stock units (RSUs). The grant was made at a stated price of $0.00 per share as a compensation award, not an open-market purchase.
The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date, June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in Chimera common stock on vesting. Following this grant, Walsh directly holds 26,765 shares of Chimera common stock, including the unvested RSUs. Each RSU has the economic equivalent of one share of Chimera common stock.
Reilly Brian Patrick reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Brian Patrick Reilly received an equity grant of 11,263 restricted stock units (RSUs) of common stock. The RSUs vest on the earlier of the first anniversary of the June 11, 2026 grant date or the next annual stockholders meeting and will be settled entirely in Chimera common shares. After this award, Reilly holds 106,133 shares of common stock, reflecting a compensation-related grant rather than an open-market purchase.
CREAGH GERARD reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Gerard Creagh received an equity award of 11,263 restricted stock units (RSUs) on Chimera common stock. The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date on June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in shares of common stock. After this grant, Creagh directly holds 188,015 shares of Chimera common stock. This is a compensation-related grant rather than an open‑market purchase.